Top

Published in:

01-12-2007 | Lab. Investigation-Human/Animal Tissue

No association of MDM2 SNP309 with risk of glioblastoma and prognosis

Authors: Soufiane El Hallani, Yannick Marie, Ahmed Idbaih, Mathieu Rodero, Blandine Boisselier, Florence Laigle-Donadey, François Ducray, Jean-Yves Delattre, Marc Sanson

Published in: Journal of Neuro-Oncology | Issue 3/2007

Abstract

The MDM2 SNP309 variant has been shown to increase MDM2 expression and to be associated with tumor formation. In glioblastomas, the P53/MDM2 pathway is of crucial importance and MDM2 amplification is related to poor prognosis. However, we show here that MDM2 SNP309 is not associated with glioblastoma risk, and is not a prognostic factor.

Behin A, Hoang-Xuan K, Carpentier AF, Delattre JY (2003) Primary brain tumours in adults. Lancet 361:323–331PubMedCrossRef

Sanson M, Thillet J, Hoang-Xuan K (2004) Molecular changes in gliomas. Curr Opin Oncol 16:607–613PubMedCrossRef

Houillier C, Lejeune J, Benouaich-Amiel A, Laigle-Donadey F, Criniere E, Mokhtari K, Thillet J, Delattre JY, Hoang-Xuan K, Sanson M (2006) Prognostic impact of molecular markers in a series of 220 primary glioblastomas. Cancer 106:2218–2223PubMedCrossRef

Bond GL, Hu W, Bond EE, Robins H, Lutzker SG, Arva NC, Bargonetti J, Bartel F, Taubert H, Wuerl P, Onel K, Yip L, Hwang SJ, Strong LC, Lozano G, Levine AJ (2004) A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 119:591–602PubMedCrossRef

Walsh CS, Miller CW, Karlan BY, Koeffler HP (2007) Association between a functional single nucleotide polymorphism in the MDM2 gene and sporadic endometrial cancer risk. Gynecol Oncol 104:660–664PubMedCrossRef

Ohmiya N, Taguchi A, Mabuchi N, Itoh A, Hirooka Y, Niwa Y, Goto H (2006) MDM2 promoter polymorphism is associated with both an increased susceptibility to gastric carcinoma and poor prognosis. J Clin Oncol 24:4434–4440PubMedCrossRef

Dharel N, Kato N, Muroyama R, Moriyama M, Shao RX, Kawabe T, Omata M (2006) MDM2 promoter SNP309 is associated with the risk of hepatocellular carcinoma in patients with chronic hepatitis C. Clin Cancer Res 12:4867–4871PubMedCrossRef

Hong Y, Miao X, Zhang X, Ding F, Luo A, Guo Y, Tan W, Liu Z, Lin D (2005) The role of P53 and MDM2 polymorphisms in the risk of esophageal squamous cell carcinoma. Cancer Res 65:9582–9587PubMedCrossRef

Onat OE, Tez M, Ozcelik T, Toruner GA (2006) MDM2 T309G polymorphism is associated with bladder cancer. Anticancer Res 26:3473–3475PubMed

10.

Campbell IG, Eccles DM, Choong DY (2006) No association of the MDM2 SNP309 polymorphism with risk of breast or ovarian cancer. Cancer Lett 240:195–197PubMedCrossRef

11.

Millikan RC, Heard K, Winkel S, Hill EJ, Heard K, Massa B, Mayes L, Williams P, Holston R, Conway K, Edmiston S, de Cotret AR (2006) No association between the MDM2-309 T/G promoter polymorphism and breast cancer in African-Americans or Whites. Cancer Epidemiol Biomarkers Prev 15:175–177PubMedCrossRef

12.

Petenkaya A, Bozkurt B, Akilli-Ozturk O, Kaya HS, Gur-Dedeoglu B, Yulug IG (2006) Lack of association between the MDM2-SNP309 polymorphism and breast cancer risk. Anticancer Res 26:4975–4977PubMed

13.

Wilkening S, Bermejo JL, Burwinkel B, Klaes R, Bartram CR, Meindl A, Bugert P, Schmutzler RK, Wappenschmidt B, Untch M, Hemminki K, Forsti A (2006) The single nucleotide polymorphism IVS1 + 309 in mouse double minute 2 does not affect risk of familial breast cancer. Cancer Res 66:646–648PubMedCrossRef

14.

Ma H, Hu Z, Zhai X, Wang S, Wang X, Qin J, Jin G, Liu J, Wang X, Wei Q, Shen H (2006) Polymorphisms in the MDM2 promoter and risk of breast cancer: a case-control analysis in a Chinese population. Cancer Lett 240:261–267PubMedCrossRef

15.

Alhopuro P, Ylisaukko-Oja SK, Koskinen WJ, Bono P, Arola J, Jarvinen HJ, Mecklin JP, Atula T, Kontio R, Makitie AA, Suominen S, Leivo I, Vahteristo P, Aaltonen LM, Aaltonen LA (2005) The MDM2 promoter polymorphism SNP309T→G and the risk of uterine leiomyosarcoma, colorectal cancer, and squamous cell carcinoma of the head and neck. J Med Genet 42:694–698PubMedCrossRef

16.

Pine SR, Mechanic LE, Bowman ED, Welsh JA, Chanock SC, Shields PG, Harris CC (2006) MDM2 SNP309 and SNP354 are not associated with lung cancer risk. Cancer Epidemiol Biomarkers Prev 15:1559–1561PubMedCrossRef

17.

Hu Z, Ma H, Lu D, Qian J, Zhou J, Chen Y, Xu L, Wang X, Wei Q, Shen H (2006) Genetic variants in the MDM2 promoter and lung cancer risk in a Chinese population. Int J Cancer 118:1275–1278PubMedCrossRef

18.

Lind H, Zienolddiny S, Ekstrom PO, Skaug V, Haugen A (2006) Association of a functional polymorphism in the promoter of the MDM2 gene with risk of nonsmall cell lung cancer. Int J Cancer 119:718–721PubMedCrossRef

19.

Li G, Zhai X, Zhang Z, Chamberlain RM, Spitz MR, Wei Q (2006) MDM2 gene promoter polymorphisms and risk of lung cancer: a case-control analysis. Carcinogenesis 27:2028–2033PubMedCrossRef

20.

Bond GL, Hirshfield KM, Kirchhoff T, Alexe G, Bond EE, Robins H, Bartel F, Taubert H, Wuerl P, Hait W, Toppmeyer D, Offit K, Levine AJ (2006) MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner. Cancer Res 66:5104–5110PubMedCrossRef

21.

Galic V, Willner J, Wollan M, Garg R, Garcia R, Goff BA, Gray HJ, Swisher EM (2007) Common polymorphisms in TP53 and MDM2 and the relationship to TP53 mutations and clinical outcomes in women with ovarian and peritoneal carcinomas. Genes Chromosomes Cancer 46:239–247PubMedCrossRef

22.

Menin C, Scaini MC, De Salvo GL, Biscuola M, Quaggio M, Esposito G, Belluco C, Montagna M, Agata S, D’Andrea E, Nitti D, Amadori A, Bertorelle R (2006) Association between MDM2-SNP309 and age at colorectal cancer diagnosis according to p53 mutation status. J Natl Cancer Inst 98:285–288PubMedCrossRef

23.

Wasielewski M, Nagel JH, Brekelmans C, Klijn JG, van den Ouweland A, Meijers-Heijboer H, Schutte M (2006) MDM2 SNP309 accelerates familial breast carcinogenesis independently of estrogen signaling. Breast Cancer Res Treat

24.

Bond GL, Menin C, Bertorelle R, Alhopuro P, Aaltonen LA, Levine AJ (2006) MDM2 SNP309 accelerates colorectal tumour formation in women. J Med Genet 43:950–952PubMedCrossRef

Title: No association of MDM2 SNP309 with risk of glioblastoma and prognosis
Authors: Soufiane El Hallani
Yannick Marie
Ahmed Idbaih
Mathieu Rodero
Blandine Boisselier
Florence Laigle-Donadey
François Ducray
Jean-Yves Delattre
Marc Sanson
Publication date: 01-12-2007
Publisher: Springer US
Published in: Journal of Neuro-Oncology / Issue 3/2007
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-007-9416-1

At a glance: The STEP trials

Springer Medicine

No association of MDM2 SNP309 with risk of glioblastoma and prognosis

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2007

Progressive multifocal leukoencephalopathy in a patient with marginal zone B-cell lymphoma

Human cytomegalovirus induces cellular tyrosine kinase signaling and promotes glioma cell invasiveness

Low HER2-expressing glioblastomas are more often secondary to anaplastic transformation of low-grade glioma

Curcumin induces G2/M cell cycle arrest in a p53-dependent manner and upregulates ING4 expression in human glioma

Pentavalent technetium-99m dimercaptosuccinic acid [99mTc-(V)DMSA] brain scintitomography—a plausible non-invasive depicter of glioblastoma proliferation and therapy response

Dual targeting of IGF-1R and PDGFR inhibits proliferation in high-grade gliomas cells and induces radiosensitivity in JNK-1 expressing cells